Morningstar: aandeel in de kijker is UCB SA (8/4/2014)

Growth from new drugs has yet to offset genericization, keeping UCB's moat trend stable.

With blockbuster drugs Zyrtec and Keppra, UCB has emerged as a major biopharmaceutical player. However, given the patent expiration of its former flagship products, the company has struggled in recent years to fill the gap through acquisitions and developing its pipeline products. We are cautiously optimistic that growth will resume in the midterm as new drugs reach critical mass and help improve operating leverage.

Lees het volledige rapport

Meer actuele koersen vindt u hier